Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer. The company’s clinical-stage product candidates include AVP-786, which is in Phase II clinical trial for the treatment of neurologic and psychiatric disorders, including…More pain, behavioral disorders, mood disorders, and movement disorders; CTP-499 that is in Phase II clinical trial for chronic kidney disease in patients with type 2 diabetes; and CTP-354, which is in Phase I clinical trial to spasticity associated with spinal cord injury and multiple sclerosis.
Social Media Links
REPORT RATINGS
4.8 / 5.0 (174)
Concert Pharmaceuticals Inc reports have an aggregate usefulness score of 4.8 based on 174 reviews.